Hla Alloantibody Detection
Hla Alloantibody Detection - Related Videos
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
0 Views •
Cited by 2 •
2017
Mismatches in human leukocyte antigen (HLA) sequences between organ donor and recipient pairs are the major cause of antibody-mediated rejection in organ transplantation. Here we present the use of custom antigen arrays that are based on individual donors' HLA sequences to probe anti-donor HLA alloantibodies in organ recipients.
03:15
A Peptide Array-Based Detection of Anti-donor HLA Alloantibodies in Organ Recipients
0 Views •
2025
This video demonstrates an assay to detect anti-donor HLA alloantibodies in organ recipients. A peptide array is synthesized to represent potential epitopes for antibody-mediated organ rejection. The array is incubated with the recipient's serum, containing alloantibodies that bind to their target epitopes. Antibody binding is detected using chemiluminescence to identify donor-specific HLA epitopes that incite alloantibody reactivity.
07:18
HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
0 Views •
Cited by 17 •
2011
A new DC independent method for induction and expansion of antigen-specific T cells is described. HLA A2-Ig based artificial Antigen Presenting Cells (aAPC) are loaded with HLA-A2 restricted peptides to efficiently expand CTL of diverse antigen specificity. This technology holds great potential for CTL-based adoptive immunotherapy.
09:10
Combination of Adhesive-tape-based Sampling and Fluorescence in situ Hybridization for Rapid Detection of Salmonella on Fresh Produce
0 Views •
Cited by 17 •
2010
This protocol describes a simple adhesive-tape-based approach for sampling of tomato and other fresh produce surfaces, followed by rapid whole cell detection of Salmonella using fluorescence in situ hybridization (FISH).
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
0 Views •
Cited by 2 •
2021
Based on a hepatitis B virus (HBV)-derived peptide matrix, HBV-specific CD4 T-cell responses could be evaluated in parallel with identification of HBV-specific CD4 T-cell epitopes.
FAQs
Multiplex bead-based assays present patient serum with beads carrying defined HLA antigens. If antibodies in the serum bind those antigens, the assay detects the interaction through fluorescent signals. Because the platform tests multiple defined targets, the resulting pattern can help characterize which nonself HLA molecules are recognized rather than providing only a general indication of antibody presence.
The signal reflects antibody binding between patient immunoglobulins and nonself HLA molecules displayed by the assay system. Serum is exposed to defined antigens, and binding is converted into a measurable fluorescent readout. In biochemical terms, this links antigen-antibody recognition to an analytical signal that allows laboratory assessment of HLA-directed reactivity.
Bead-based testing examines serum reactivity against defined HLA antigens, whereas a crossmatch assesses whether the patient’s antibodies react with cells from a particular donor. The two approaches therefore answer related but different questions: one helps characterize antibody specificity, while the other evaluates compatibility with donor material and can reveal donor-directed reactivity relevant to transplantation.
The clinical relevance of an antibody depends partly on whether its target is present in the proposed donor. Identifying donor-specific antibody risk connects the patient’s broader sensitization profile with an individual transplant decision. This distinction supports donor selection because antibodies directed toward donor HLA molecules may indicate greater concern than reactivity against antigens absent from that donor.
A typical assessment begins with patient serum testing against defined HLA antigens, often using a multiplex, bead-based platform and fluorescent detection. Laboratory findings can then be considered alongside a donor-cell crossmatch to assess donor-directed reactivity. Together, these results help estimate sensitization and inform donor selection before transplantation rather than relying on a single measurement alone.
Repeating antibody assessment after transplantation allows clinicians to observe changes in antibody levels over time. When interpreted with other clinical information, these trends can contribute to evaluating possible graft injury and guiding management. The measurements are therefore useful not only for pre-transplant compatibility assessment but also for following immunologic developments after the graft has been placed.